MTC Glossary of terms

From Medullary Thyroid Cancer
Revision as of 04:12, 22 August 2020 by Mtc admin (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
ACTH
Adrenocorticotropic hormone
AJCC
American Joint Committee on Cancer
ATA
American Thyroid Association
CCH
C-cell hyperplasia
CEA
Carcinoembryonic antigen
CLA
Cutaneous lichen amyloidosis
CRH
Corticotropin-releasing hormone
CT
Computed tomography (tomographic)
Ctn
Calcitonin
EBRTa
External beam radiation therapy
EMA
European Medicines Agency
FDA
U.S. Food and Drug Administration
FDG-PET
2-[Fluorine-18]fluoro-2-deoxy-D-glucosepositron emission tomography
F-DOPA
18F-dihydroxyphenylalanine
FMTC
Familial medullary thyroid cancer
FNA
Fine-needle aspiration
FTC
Follicular thyroid carcinoma
HD
Hirschsprung’s disease
HIPAA
Health Insurance Portability and Accountability Act
HPTH
Hyperparathyroidism
HR
Hazard ratio
ICMA
Immunochemiluminometric assay
IHC
Immunohistochemical
IMRT
Intensity-modulated radiation therapy
MEN
Multiple endocrine neoplasia
Met
Metastasis
MIBG
Metaiodobenzylguanidine
MRI
Magnetic resonance imaging
MTC
Medullary thyroid carcinoma
NCT
National Clinical Trial
OMIM
Online Mendelian Inheritance in Man
PEG
Percutaneous gastrostomy
PFS
Progression-free survival
PGD
Preimplantation genetic diagnosis
PHEO
Pheochromocytoma
PTC
Papillary thyroid carcinoma
PTH
Parathyroid hormone
RAI
Radioactive iodine
RECIST
Response evaluation criteria in solid tumors
REMS
Risk evaluation and mitigation strategies
RET
REarranged during Transfection protooncogene
SEER
Surveillance, Epidemiology, and End Results
TKI
Tyrosine kinase inhibitor
TNM
Tumor, node, metastases
TSH
Thyrotropin
US
Ultrasound
VEGF
Vascular endothelial growth factor